Literature DB >> 24102798

Norepinephrine transporter heterozygous knockout mice exhibit altered transport and behavior.

H M Fentress1, R Klar, J J Krueger, T Sabb, S N Redmon, N M Wallace, J K Shirey-Rice, M K Hahn.   

Abstract

The norepinephrine (NE) transporter (NET) regulates synaptic NE availability for noradrenergic signaling in the brain and sympathetic nervous system. Although genetic variation leading to a loss of NET expression has been implicated in psychiatric and cardiovascular disorders, complete NET deficiency has not been found in people, limiting the utility of NET knockout mice as a model for genetically driven NET dysfunction. Here, we investigate NET expression in NET heterozygous knockout male mice (NET(+/-) ), demonstrating that they display an approximately 50% reduction in NET protein levels. Surprisingly, these mice display no significant deficit in NET activity assessed in hippocampal and cortical synaptosomes. We found that this compensation in NET activity was due to enhanced activity of surface-resident transporters, as opposed to surface recruitment of NET protein or compensation through other transport mechanisms, including serotonin, dopamine or organic cation transporters. We hypothesize that loss of NET protein in the NET(+/-) mouse establishes an activated state of existing surface NET proteins. The NET(+/-) mice exhibit increased anxiety in the open field and light-dark box and display deficits in reversal learning in the Morris water maze. These data suggest that recovery of near basal activity in NET(+/-) mice appears to be insufficient to limit anxiety responses or support cognitive performance that might involve noradrenergic neurotransmission. The NET(+/-) mice represent a unique model to study the loss and resultant compensatory changes in NET that may be relevant to behavior and physiology in human NET deficiency disorders.
© 2013 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  Anxiety; Morris water maze; depression; genetic; heterozygote; knockout; light-dark box; norepinephrine; tail suspension; transporter

Mesh:

Substances:

Year:  2013        PMID: 24102798      PMCID: PMC3852905          DOI: 10.1111/gbb.12084

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  95 in total

1.  Overexpression of alpha2C-adrenoceptors impairs water maze navigation.

Authors:  M Björklund; J Sirviö; M Riekkinen; J Sallinen; M Scheinin; P Riekkinen
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder.

Authors:  Chun-Hyung Kim; Maureen K Hahn; Yoosook Joung; Susan L Anderson; Angela H Steele; Michelle S Mazei-Robinson; Ian Gizer; Martin H Teicher; Bruce M Cohen; David Robertson; Irwin D Waldman; Randy D Blakely; Kwang-Soo Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

Review 3.  Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder.

Authors:  J Biederman; T Spencer
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

Review 4.  Role of norepinephrine in the pathophysiology and treatment of mood disorders.

Authors:  K J Ressler; C B Nemeroff
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

5.  Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain.

Authors:  Anne Amphoux; Vincent Vialou; Eva Drescher; Michael Brüss; Clotilde Mannoury La Cour; Catherine Rochat; Mark J Millan; Bruno Giros; Heinz Bönisch; Sophie Gautron
Journal:  Neuropharmacology       Date:  2006-03-31       Impact factor: 5.250

6.  Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension.

Authors:  N R Keller; A Diedrich; M Appalsamy; L C Miller; M G Caron; M P McDonald; R C Shelton; R D Blakely; D Robertson
Journal:  Neuroscience       Date:  2006-03-03       Impact factor: 3.590

7.  Effect of antidepressant drugs in mice lacking the norepinephrine transporter.

Authors:  Marta Dziedzicka-Wasylewska; Agata Faron-Górecka; Maciej Kuśmider; Elzbieta Drozdowska; Zofia Rogóz; Joanna Siwanowicz; Marc G Caron; Heinz Bönisch
Journal:  Neuropsychopharmacology       Date:  2006-03-22       Impact factor: 7.853

8.  The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes.

Authors:  K Brookes; X Xu; W Chen; K Zhou; B Neale; N Lowe; R Anney; R Aneey; B Franke; M Gill; R Ebstein; J Buitelaar; P Sham; D Campbell; J Knight; P Andreou; M Altink; R Arnold; F Boer; C Buschgens; L Butler; H Christiansen; L Feldman; K Fleischman; E Fliers; R Howe-Forbes; A Goldfarb; A Heise; I Gabriëls; I Korn-Lubetzki; L Johansson; R Marco; S Medad; R Minderaa; F Mulas; U Müller; A Mulligan; K Rabin; N Rommelse; V Sethna; J Sorohan; H Uebel; L Psychogiou; A Weeks; R Barrett; I Craig; T Banaschewski; E Sonuga-Barke; J Eisenberg; J Kuntsi; I Manor; P McGuffin; A Miranda; R D Oades; R Plomin; H Roeyers; A Rothenberger; J Sergeant; H-C Steinhausen; E Taylor; M Thompson; S V Faraone; P Asherson
Journal:  Mol Psychiatry       Date:  2006-08-08       Impact factor: 15.992

Review 9.  Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.

Authors:  Hermann Koepsell; Katrin Lips; Christopher Volk
Journal:  Pharm Res       Date:  2007-05-01       Impact factor: 4.580

10.  Norepinephrine transporter variant A457P knock-in mice display key features of human postural orthostatic tachycardia syndrome.

Authors:  Jana K Shirey-Rice; Rebecca Klar; Hugh M Fentress; Sarah N Redmon; Tiffany R Sabb; Jessica J Krueger; Nathan M Wallace; Martin Appalsamy; Charlene Finney; Suzanna Lonce; André Diedrich; Maureen K Hahn
Journal:  Dis Model Mech       Date:  2013-04-04       Impact factor: 5.758

View more
  8 in total

1.  mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome.

Authors:  Rocco G Gogliotti; Rebecca K Senter; Nicole M Fisher; Jeffrey Adams; Rocio Zamorano; Adam G Walker; Anna L Blobaum; Darren W Engers; Corey R Hopkins; J Scott Daniels; Carrie K Jones; Craig W Lindsley; Zixiu Xiang; P Jeffrey Conn; Colleen M Niswender
Journal:  Sci Transl Med       Date:  2017-08-16       Impact factor: 17.956

2.  The impact of noradrenergic neurotoxin DSP-4 and noradrenaline transporter knockout (NET-KO) on the activity of liver cytochrome P450 3A (CYP3A) in male and female mice.

Authors:  Ewa Bromek; Przemysław Jan Danek; Jacek Wójcikowski; Agnieszka Basińska-Ziobroń; Renata Pukło; Joanna Solich; Marta Dziedzicka-Wasylewska; Władysława Anna Daniel
Journal:  Pharmacol Rep       Date:  2022-08-26       Impact factor: 3.919

3.  A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism.

Authors:  F Z Marques; N Eikelis; R G Bayles; E A Lambert; N E Straznicky; D Hering; M D Esler; G A Head; D A Barton; M P Schlaich; G W Lambert
Journal:  Mol Psychiatry       Date:  2016-04-05       Impact factor: 15.992

4.  Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu3) impairs postsynaptic plasticity and modulates affective behaviors.

Authors:  Max E Joffe; Chiaki I Santiago; Sheryl Anne D Vermudez; Nicole M Fisher; Shalini Dogra; Colleen M Niswender; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2021-05-25       Impact factor: 7.853

Review 5.  Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.

Authors:  Shreyas Bhat; Ali El-Kasaby; Michael Freissmuth; Sonja Sucic
Journal:  Pharmacol Ther       Date:  2020-12-10       Impact factor: 12.310

6.  Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol.

Authors:  Sufei He; Miao Wang; Jinhua Si; Tianyi Zhang; Hong Cui; Xiumei Gao
Journal:  BMJ Open       Date:  2018-02-20       Impact factor: 2.692

7.  Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus.

Authors:  Xiangdong Du; Ming Yin; Lian Yuan; Guangya Zhang; Yan Fan; Zhe Li; Nian Yuan; Xiaoli Lv; Xueli Zhao; Siyun Zou; Wei Deng; Thomas R Kosten; Xiang Yang Zhang
Journal:  Transl Psychiatry       Date:  2020-05-04       Impact factor: 6.222

8.  Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease.

Authors:  Jacki M Rorabaugh; Termpanit Chalermpalanupap; Christian A Botz-Zapp; Vanessa M Fu; Natalie A Lembeck; Robert M Cohen; David Weinshenker
Journal:  Brain       Date:  2017-11-01       Impact factor: 15.255

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.